Results 251 to 260 of about 8,070,232 (284)

CA 19-9 in Pancreatic Cancer

Surgical Oncology Clinics of North America, 1998
CA 19-9 has achieved a defined role in the diagnosis, prognosis, and monitoring of patients with pancreatic cancer. For diagnosis, a reference value above 200 u/mL in a nonjaundiced patient with a confirming CT scan has a very high predictive value.
R E, Ritts, H A, Pitt
openaire   +2 more sources

The rise and fall of CA 19-9

South African Journal of Surgery, 2013
Tumour markers abound in the field of gastroenterology. One of the most ubiquitous is carbohydrate antigen 19-9 (CA 19-9), which was first described by Koprowski et al. in 1979 as an abnormal glycoprotein, expressed on the surface of colorectal cell lines.
Bernon, M, Thomson, S R, Jonas, E
openaire   +3 more sources

Comparison of Different Immunoassays for CA 19-9

Clinical Chemistry and Laboratory Medicine, 2001
We compared six routinely employed immunoassay kits: Architect i2000 and AxSYM, Abbott Laboratories; Elecsys 2010, Roche Diagnostics; ELSA, CIS-BioInternational; Immulite 1, Diagnostic Products Corporation; and IRMA-mat, Byk-Sangtec Diagnostica. Using all analytical systems, we measured identical groups of clinical samples completed with selected ...
P, Stern, B, Friedecky, V, Bartos, D, Bezdickova, J, Vavrova, J, Uhrova, L, Rozprimova, T, Zima, V, Palicka   +8 more
openaire   +2 more sources

Comparison of three immunoassays for CA 19-9

Clinica Chimica Acta, 2009
Carbohydrate antigen (CA) 19-9 is a valuable tumor marker for gastrointestinal (GI) cancers, but results obtained by different assays vary and a change of method during follow-up may cause problems.We determined CA 19-9 using Abbott i2000 Architect (CA 19-9XR assay), Roche Elecsys 2010 and Bayer Immuno 1 analyzers.
Kristina, Hotakainen, Pirjo, Tanner, Henrik, Alfthan, Caj, Haglund, Ulf-Håkan, Stenman   +4 more
openaire   +2 more sources

CA 19-9: Biochemical and Clinical Aspects

2015
CA19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9 or sialylated Lewis a antigen) is the most commonly used and best validated serum tumor marker for pancreatic cancer diagnosis in symptomatic patients and for monitoring therapy in patients with pancreatic adenocarcinoma.
Scara', Salvatore, Bottoni, Patrizia, Scatena, Roberto   +2 more
openaire   +5 more sources

Der Tumormarker CA 19-9

Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, 2017
Im Rahmen von malignen Erkrankungen nimmt die Bestimmung von Tumormarkern im Serum einen wesentlichen Bestandteil der Diagnostik, Verlaufskontrolle und Therapieuberwachung ein. CA 19-9 ist der Marker bei Pankreaskarzinomen, da er hier die hochste Sensitivitat und Spezifitat zeigt, jedoch kann dieser auf keinen Fall zur Fruhdiagnostik eingesetzt werden.
K. Passek, M. H. Bendels, D. Ohlendorf, E. Wanke, G. M. Oremek, D. A. Groneberg   +5 more
openaire   +1 more source

Is CA 19-9 a screening marker?

Digestive and Liver Disease, 2009
CA 19-9 a screening ...
BARUGOLA, Giuliano, FRULLONI, Luca, SALVIA, Roberto, FALCONI, Massimo   +3 more
openaire   +4 more sources

Clinical usefulness of CA-19-9 in pancreatic carcinoma

Seminars in Surgical Oncology, 1998
Preoperative and postoperative serum levels of carbohydrate antigen-(CA)19-9 in 148 patients with carcinoma of the pancreas were studied. All 18 patients with carcinoma of the pancreas of Stage I, II, and III were resectable, and their pre-operative serum levels of CA-19-9 were under 1,344 U/ml.
A, Nakao, K, Oshima, S, Nomoto, S, Takeda, T, Kaneko, T, Ichihara, T, Kurokawa, T, Nonami, H, Takagi   +8 more
openaire   +2 more sources

Rheumatoid factor interference in the determination of carbohydrate antigen 19-9 (CA 19-9)

Clinical Chemistry and Laboratory Medicine (CCLM), 2006
AbstractClin Chem Lab Med 2006;44:1137–9.
Mario, Berth, Eugene, Bosmans, Jacques, Everaert, Jan, Dierick, Johan, Schiettecatte, Ellen, Anckaert, Joris, Delanghe   +6 more
openaire   +2 more sources